Showing 1 - 3 results of 3 for search 'Javier Ortego', query time: 0.02s Refine Results
  1. 1
    The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus

    The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus by Luis Jiménez-Cabello, Luis Jiménez-Cabello, Sergio Utrilla-Trigo, Miguel Illescas-Amo, Karen Rodríguez-Sabando, Julio Benavides-Silván, Eva Calvo-Pinilla, Javier Ortego

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

    A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. by Javier Castillo-Olivares, Eva Calvo-Pinilla, Isabel Casanova, Katarzyna Bachanek-Bankowska, Rachael Chiam, Sushila Maan, Jose Maria Nieto, Javier Ortego, Peter Paul Clement Mertens

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

    Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. by Tamara Kusay Jabbar, Eva Calvo-Pinilla, Francisco Mateos, Simon Gubbins, Abdelghani Bin-Tarif, Katarzyna Bachanek-Bankowska, Oya Alpar, Javier Ortego, Haru-Hisa Takamatsu, Peter Paul Clement Mertens, Javier Castillo-Olivares

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: